EXAS Earnings Prediction
The chart below shows how EXAS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EXAS sees a +1.58% change in stock price 10 days leading up to the earnings, and a +0.83% change 10 days following the report. On the earnings day itself, the stock moves by -0.21%. This data can give you a slight idea of what to expect for the next quarter's release.
EXAS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
708.65M
12.78%
1.34%
Gross Margin
68.88%
-0.92%
-0.92%
Operating Margin
-2.92%
-367.89%
12.74%
Net Margin
-5.40%
-4253.85%
138.94%
EPS
-0.21
--
133.33%
No Data Available
EXAS Earnings Analysis
Exact Sciences Corp Corporation (EXAS.O) Earnings Conference Call
Positive
Revenue Growth Momentum: Total revenue grew 13% year-over-year to $709 million, driven by broad-based momentum in Cologuard adoption and international expansion of Oncotype DX.
EBITDA Margin Expansion: Adjusted EBITDA margin expanded 500 basis points to 14%, highlighting another strong quarter of operational execution from the team.
Record Free Cash Flow: Generated a record $113 million in free cash flow, up nearly 60% sequentially, ending the quarter with cash and securities of more than $1 billion.
Screening and Oncology Revenue Growth: Screening revenue grew 15% to $545 million, driven by Cologuard volume, with Precision Oncology revenue growing 5% to $164 million, led by Oncotype DX, which expanded 28% internationally.
Cologuard Plus Performance Standard: Cologuard Plus sets a new performance standard with 95% cancer sensitivity and 94% specificity, enhancing the company's competitive position in the market.
Negative
Revenue Growth Analysis: Total revenue grew 13% year-over-year to $709 million, but this growth was not at the levels expected historically.
EBITDA Margin Decline: Adjusted EBITDA margin expanded 500 basis points to 14%, indicating a decline in operational efficiency compared to previous quarters.
Screening Revenue Performance: The screening revenue grew 15% to $545 million, driven by Cologuard volume, but this was below expectations for the quarter.
Cologuard Order Growth Decline: Cologuard orders have grown below the historical rate, which has negatively impacted revenue projections for the fourth quarter.
Hurricane Disruptions Impact Orders: The company faced disruptions from hurricanes, which negatively impacted Cologuard orders and results in September and October.
EXAS FAQs
How does EXAS typically perform around its earnings report dates?
Is Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
EXAS Earning Call Sentiment
Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
EXAS.O
-2.52%Positive
The earnings call reveals mixed signals: strong growth in Cologuard and Oncotype DX, and record free cash flow are positive. However, challenges like hurricane disruptions, slower-than-expected sales returns, and regulatory pressures pose risks. The Q&A highlights management's accountability for underperformance and lack of clarity on future impacts, which tempers optimism. Despite improved EBITDA guidance, the unchanged revenue guidance and external risks suggest a neutral outlook. Without market cap data, the prediction remains neutral, balancing positive financials against operational challenges and external uncertainties.
